Year: 2023

Biocytogen27s_LOGO-1

Biocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008

BEIJING--(BUSINESS WIRE)--#Biocytogen--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co.,...

logo-39

China Performs First Cancer Patient Treatments in the Xiamen Humanity Hospital Using Novel Accelerator-based Radiation Oncology Therapy (BNCT)

Neuboron develops an advanced in-hospital NeuPex AB-BNCT medical system for clinical use at XHH Research Center. XIAMEN, China--(BUSINESS WIRE)--Neuboron Medical...

logo-38

China Autonomous Driving Algorithm Research Report 2023: Promoting Developments of an End-to-End Autonomous Driving Framework – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "China Autonomous Driving Algorithm Research Report, 2023" report has been added to ResearchAndMarkets.com's offering. BEV Drives Algorithm Revolution,...